'Antiphospholipid' (aPL) antibodies are of clinical importance because
of their strong association with vascular thrombosis, recurrent pregn
ancy loss, thrombocytopenia and other clinical manifestations like liv
edo reticularis, chorea and cardiac valvular disease(1). While aPL ant
ibodies have traditionally been thought to be directed against negativ
ely-charged (anionic) phospholipids, current evidence suggests that th
ese autoantibodies recognise protein-phospholipid complexes or the pro
teins themselves(2-4). A number of candidate proteins have been invest
igated with the two most extensively researched being beta(2)-glycopro
tein I and prothrombin.